WELLESLEY, Mass., Oct. 9 /PRNewswire/ -- Xceed Molecular Corporation, a pioneer in the development of cost-effective, easy-to-use gene-expression analysis systems, announced today that Fran Tuttle has been appointed to Xceed's board of directors. Ms. Tuttle is president and chief executive officer of HX Diagnostics, a California-based company focused on developing a point-of-care diagnostic for avian flu.
"Fran is the ideal complement to our board," said Xceed's President and CEO, David Deems. "She has more than 20 years of leadership in the diagnostics industry -- including significant experience with commercialization of novel technologies. Her knowledge, counsel, and close connections with thought leaders in the field will be invaluable to us as we continue to further develop our products and solutions for multiplexed gene-expression tests for clinical research today, and in vitro diagnostics tomorrow."
Prior to HX Diagnostics, Ms. Tuttle was president and chief executive officer of Protedyne Corporation (now part of LabCorp), which developed robotics for the molecular-diagnostic-testing industry. Previously, she was senior vice president of near patient testing at Bayer Diagnostics, one of the world's largest diagnostic companies. At Bayer, she was responsible for a worldwide business of $400 million. Before joining Bayer Diagnostics, she spent 20 years at Chiron Diagnostics (formerly Ciba Corning Diagnostics), a leader in molecular and immunodiagnostics. Ms. Tuttle began her career as a CPA at Peat, Marwick, Mitchell and Company (now KPMG). She holds a master's in business administration from Harvard Business School as well as bachelor's degrees in accounting from the University of North Carolina at Chapel Hill and German from Duke University.
About Xceed Molecular
Xceed's vision is to advance molecular diagnostics and improve health outcomes by providing a cost-effective, automated system and services that facilitate the rapid translation of novel multiplexed genomic tests from research into routine clinical use. We designed our proprietary system to perform multiplexed molecular assays with superior accuracy, reproducibility, speed, and scalability at significantly lower cost than conventional array- or PCR-based systems. Our offerings include: the Ziplex(TM) System for automated gene-expression analysis, comprising an automated workstation, TipChip consumable arrays, and reagents (available in the US and Canada for research use only); Signature Chips -- pre-configured arrays focusing on a number of specific disease targets; and custom array services. Xceed's R&D and manufacturing operations are headquartered in Toronto, Ontario, with executive offices in Wellesley, Massachusetts. For more information, visit www.Xceedmolecular.com.
CONTACT: Media, Caroline Grossman, +1-781-771-5579,
caroline.grossman@gmail.com, or Company Contact, David Deems,
+1-617-899-5597, ddeems@xceedmolecular.com, both of Xceed Molecular
Corporation
Web site: http://www.xceedmolecular.com/
